Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen

Leukemia

Volumn 31, Issue 8, 2017, Pages 1788-1797

  Rafiq, S ^a   Purdon, T J ^a   Daniyan, A F ^a   Koneru, M ^a   Dao, T ^a   Liu, C ^b   Scheinberg, D A ^a,c   Brentjens, R J ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EUREKA THERAPEUTICS   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; HLA A ANTIGEN; T LYMPHOCYTE RECEPTOR; WT1 PROTEIN; HYBRID PROTEIN; INTERLEUKIN 12; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTERNAL RIBOSOME ENTRY SITE; LEUKEMIA; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL LINE; GENETICS; IMMUNOLOGY; OVARIAN NEOPLASMS; RETROVIRIDAE;

ANIMALS; CELL LINE; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; LEUKEMIA; MICE; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; TRANSCRIPTOME; WT1 PROTEINS;

EID: 85007583972     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.373     Document Type: Article

References (44)

1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra38.
2. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.
3. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-528.
4. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
5. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7: 303ra139.
6. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822-1826.
7. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540-549.
8. Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR et al. Phase I studies of central-memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. Blood 2016; 127: 2980-2990.
9. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T cells forward. Nat Rev Clin Oncol 2016; 13: 370-383.
10. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 2010; 40: 377-387.
11. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006; 15: R196-R201.
12. Morrison AA, Viney RL, Ladomery MR. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta 2008; 1785: 55-62.
13. Davies R, Moore A, Schedl A, Bratt E, Miyahawa K, Ladomery M et al. Multiple roles for the Wilms' tumor suppressor, WT1. Cancer Res 1999; 59: 1747s-1750s, discussion 51s.
14. Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 2015; 6: 36.
15. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
16. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-1704.
17. Dao T, Scheinberg DA. Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol 2008; 21: 391-404.
18. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171-179.
19. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010; 59: 1467-1479.
20. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013; 5: 176ra33.
21. Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res 2014; 20: 4036-4046.
22. Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 2014; 123: 3296-3304.
23. Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol 2015; 33: 1079-1086.
24. Fraietta JA, Schwab RD, Maus MV. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol 2016; 43: 291-299.
25. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M et al. Tumortargeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119: 4133-4141.
26. Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 2015; 29: 415-422.
27. Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014; 63: 419-435.
28. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. Oncoimmunology 2015; 4: e994446.
29. Ghani K, Wang X, de Campos-Lima PO, Olszewska M, Kamen A, Riviere I et al. Efficient human hematopoietic cell transduction using RD114-and GALVpseudotyped retroviral vectors produced in suspension and serum-free media. Hum Gene Ther 2009; 20: 966-974.
30. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 2010; 16: 3594-3606.
31. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13: 5426-5435.
32. Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 2006; 12: 5511-5519.
33. Lund RJ, Loytomaki M, Naumanen T, Dixon C, Chen Z, Ahlfors H et al. Genome-wide identification of novel genes involved in early Th1 and Th2 cell differentiation. J Immunol 2007; 178: 3648-3660.
34. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21: 713-758.
35. Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia 2015; 29: 2238-2247.
36. Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol 2014; 193: 5733-5743.
37. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21: 581-590.
38. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigenindependent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011; 71: 5697-5706.
39. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010; 70: 6725-6734.
40. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18: 1672-1683.
41. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36: 133-151.
42. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557.
43. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-924.
44. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013; 5: 174ra27.